Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS gets more than R3 Million for HIV/Aids activities
2007-12-13

 

In the picture are some of the members of the project team. From the left are: Mr Pieter du Plessis (Finances), Ms Estelle Heideman (HIV/Aids Co-ordinator: Lengau Agri Development Centre) and Rev Jaftha.
 

UFS gets more than R3 Million for HIV/Aids activities

The Chief Directorate: Community Service at the University of the Free State (UFS) has received more than R3 million to intensify activities regarding HIV/AIDS at all UFS campuses for the next seventeen months.

Higher Education HIV/AIDS Programme (HEAIDS) contributed R3 127 207 and the UFS R615 116 towards this initiative. The money will be used to implement intervention strategies from 1 January 2008 to 31 May 2009.

“The mandate poses an extensive challenge and puts pressure on the institution, but at the same time creates some incredible opportunities for intervention,” said the Chief Director of Community Service and Project Co-ordinator, Rev. Kiepie Jaftha.

HEAIDS is a nationally co-ordinated initiative to develop and strengthen the capacity of South African higher education institutions to respond to the causes, challenges and consequences of the HIV/AIDS pandemic in the sector. It is an initiative of the Department of Education and the implementing agency is Higher Education South Africa (HESA), an organisation representing vice-chancellors of tertiary institutions in South Africa.

The proposed areas and actions of intervention are categorised into three main components, namely:

- Prevention, treatment, care and support aimed at both students and staff on all UFS campuses.
Incorporation of HIV/AIDS issues into the teaching offerings of the UFS and the development of a formal policy in this regard.

- Implementation of an integrated management information system to empower stakeholders to make decisions and adapt actions by visualising facts, actions and progress on the overall HIV/AIDS programme.

The UFS met all the requirements of HEAIDS to qualify for this funding. A five-member team was formed to come up with a document entitled The Quest for an AIDS Competent Society that met the required standards.

“Each institution of higher learning had to identify and establish a project team, appoint a project leader, assign responsibilities to members of the team with different expertise, analyse the needs of the institution, and define and agree on projects in order to access the grant,” said Rev. Jaftha.

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt.stg@ufs.ac.za  
13 December 2007

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept